ADD-How much can myeloma patients learn from support groups?
In this weeks video, Dr. Brian G.M. Durie discusses the ways patients can learn from one another at IMF-affiliated support groups.The BOTTOM LINE: Support groups are a great way to find out about... Author: InternationalMyelomaFoundation Added: 08/06/2018
This study aimed to derive and validate a new risk assessment model (RAM) for IMiD-associated VTE. METHODS: Patients with newly diagnosed MM receiving IMiDs were selected from the SEER-Medicare database (n=2,397) to derive a RAM and then data from the Veterans Health Administration database (n=1,251) were used to externally validate the model. A multivariable cause-specific Cox regression model was used for model development. RESULTS: The final RAM, named the "SAVED" score, included 5 clinical variables: prior surgery, Asian race, VTE history, age ≥80 years, and dexamethasone dose. The model stratified...
Condition: Multiple Myeloma Interventions: Drug: Chidamide+VRD; Drug: VRD Sponsor: The First Affiliated Hospital of Soochow University Recruiting
We report a case of Nocardia farcinica ruptured intracranial mycotic aneurysm associated with bortezomib and corticosteroid treatment in a multiple myeloma patient. The patient was treated with trimethoprim-sulfamethoxazole and moxifloxacin together with surgical repairment of intracranial mycotic aneurysm.
Publication date: Available online 18 July 2019Source: The Lancet HaematologyAuthor(s): Saad Zafar Usmani, Fredrik Schjesvold, Albert Oriol, Lionel Karlin, Michele Cavo, Robert M Rifkin, Habte Aragaw Yimer, Richard LeBlanc, Naoki Takezako, Robert Donald McCroskey, Andrew Boon Ming Lim, Kenshi Suzuki, Hiroshi Kosugi, George Grigoriadis, Irit Avivi, Thierry Facon, Sundar Jagannath, Sagar Lonial, Razi Uddin Ghori, Mohammed Z H FarooquiSummaryBackgroundLenalidomide and dexamethasone has been a standard of care in transplant-ineligible patients with newly diagnosed multiple myeloma. The addition of a third drug to the combinati...
Publication date: Available online 18 July 2019Source: The Lancet HaematologyAuthor(s): Maria-Victoria Mateos, Hilary Blacklock, Fredrik Schjesvold, Albert Oriol, David Simpson, Anupkumar George, Hartmut Goldschmidt, Alessandra Larocca, Asher Chanan-Khan, Daniel Sherbenou, Irit Avivi, Noam Benyamini, Shinsuke Iida, Morio Matsumoto, Kenshi Suzuki, Vincent Ribrag, Saad Z Usmani, Sundar Jagannath, Enrique M Ocio, Paula Rodriguez-OteroSummaryBackgroundPomalidomide and dexamethasone is a standard of care for patients with multiple myeloma in whom bortezomib and lenalidomide treatment has failed. KEYNOTE-183 assessed efficacy an...
Publication date: Available online 18 July 2019Source: The Lancet HaematologyAuthor(s): Caitlin Costello
SAN DIEGO, July 19, 2019 -- (Healthcare Sales &Marketing Network) -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced that Janssen-Cilag International NV (Janssen) ... Biopharmaceuticals, Oncology, Drug Delivery, Regulatory Halozyme Therapeutics, Janssen, DARZALEX, daratumumab, multiple myeloma
ConclusionIn a cohort of 40 older adults with newly diagnosed multiple myeloma, three frailty indices have differing approaches to operationalizing frailty resulting, in different patients being categorized as frail. Little agreement existed between the models. Further studies are needed to explore the utility of these models in predicting treatment toxicity and prognosis.
Publication date: Available online 17 July 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Fernando Cabanillas, Noridza Rivera, Mirelis Acosta, Wandaly Pardo, Pedro Solivan, Caroline Rivera, Idalia LiboyAbstractBackgroundOur objective was to evaluate the impact of lenalidomide in patients with aggressive lymphoma who attained
Conditions: Non-Small Cell Lung Cancer; Ovarian Cancer; Fallopian Tube Cancer; Triple Negative Breast Cancer; Multiple Myeloma; Pancreatic Ductal Adenocarcinoma Interventions: Biological: CART-TnMUC1; Drug: Cyclophosphamide; Drug: Fludarabine Sponsor: Tmunity Therapeutics Not yet recruiting